Fund shareholders of LIXTE BIOTECHNOLOGY HOLDINGS INC
ISIN US5393193017 · United States · LEI 5493004HPIB1PBNQ3L69
- Fund shareholders
- 5
- Of which ETFs
- 0 5 other funds
- Value held
- 282.4K $
| Fund | Shares | Value | Weight in fund | |
|---|---|---|---|---|
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 49,479 | 151.9K $ | 0.00 % | as of Mar 31, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 28,620 | 82.7K $ | 0.00 % | as of Feb 28, 2026 ↗ |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 8,516 | 24.6K $ | as of Feb 28, 2026 ↗ | |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 7,228 | 20.9K $ | as of Feb 28, 2026 ↗ | |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 775 | 2.2K $ | as of Feb 28, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of Feb 28, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 0.00 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 5 | 0 | 94,618 | +26.0 % |
| 2026Q1 | 5 | +1 | 75,070 | +62.4 % |
| 2025Q4 | 4 | 0 | 46,226 | +78.4 % |
| 2025Q3 | 4 | 0 | 25,913 | +19.2 % |
| 2025Q2 | 4 | 0 | 21,738 | -1.5 % |
| 2025Q1 | 4 | +1 | 22,075 | +46.9 % |
| 2024Q4 | 3 | 0 | 15,024 | -0.8 % |
| 2024Q3 | 3 | 0 | 15,140 | -0.4 % |
| 2024Q2 | 3 | 0 | 15,207 | 0.0 % |
| 2024Q1 | 3 | +1 | 15,207 | +52.1 % |
| 2023Q4 | 2 | 9,998 |
Institutional managers
12 managers declare this company to the SEC (Form 13F).
| Manager | Shares | Value | |
|---|---|---|---|
| SCOTIA CAPITAL INC. | 283,162 | 869.3K $ | as of Mar 31, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | 93,000 | 285.5K $ | as of Mar 31, 2026 |
| Federation des caisses Desjardins du Quebec | 64,487 | 198K $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 58,852 | 180.7K $ | as of Mar 31, 2026 |
| CITADEL ADVISORS LLC | 56,557 | 173.6K $ | as of Mar 31, 2026 |
| Ethos Financial Group, LLC | 24,808 | 76.2K $ | as of Mar 31, 2026 |
| XTX Topco Ltd | 23,446 | 72K $ | as of Mar 31, 2026 |
| STATE STREET CORP | 17,396 | 53.4K $ | as of Mar 31, 2026 |
| Atlas Legacy Advisors, LLC | 13,771 | 42.3K $ | as of Mar 31, 2026 |
| HRT FINANCIAL LP | 11,346 | 34 $ | as of Mar 31, 2026 |
| Tower Research Capital LLC (TRC) | 973 | 3K $ | as of Mar 31, 2026 |
| SBI Securities Co., Ltd. | 190 | 583 $ | as of Mar 31, 2026 |
Declared shareholders of LIXTE BIOTECHNOLOGY HOLDINGS INC
There is 1 beneficial ownership filing. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Strategic EP, LLC and 1 other | 5.10 % | 774,902 | as of Jun 4, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of LIXTE BIOTECHNOLOGY HOLDINGS INC". https://titelia.com/en/stocks/lixte-biotechnology-holdings-inc-US5393193017